Celltrion calls on UK to lower threshold for using anti-TNF therapies

South Korean firm Celltrion Healthcare (KRX: 068270) has called on the UK’s public healthcare provider, the National Health Service (NHS), to consider lowering the threshold for starting biologics in patients with rheumatoid arthritis (RA).

The firm notes that, while the percentage of patients who are treated with an anti-TNF is 24% or higher in countries such as Italy and France, in the UK the figure is just 15%.

This is due to the fact that, in the UK, a patient must have a more severe level of the disease before being considered for treatment.